India, July 21 -- Novartis AG (NVS) Tuesday reported a relatively lower second quarter income, despite generating a modest increase in net sales, driven by strong growth in its oncology portfolio. The Swiss drugmaker also reaffirmed its fiscal 2026 guidance.
Company Profile
Novartis is a Swiss innovative medicines company focused on developing and commercialising prescription drugs across cardiovascular, renal, and metabolic diseases, immunology, neuroscience, oncology, and hematology.
The company's key blockbuster products include Entresto, Cosentyx, Kisqali, Kesimpta, and Pluvicto, with Entresto and Cosentyx among its top revenue contributors.
2026 Second Quarter Highlights
For the second quarter of 2026, the company's net income dec...